Clinical Trials
3 trialsNCT03552471 2025-02-13
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02996825 2024-04-02
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03045393 2018-07-05
IMGN853
Duke University
Phase 1 Withdrawn